PT2588090T - Formas de dosagem oral farmacêuticas compreendendo dabigatrano etexilato e os seus sais farmaceuticamente aceitáveis - Google Patents
Formas de dosagem oral farmacêuticas compreendendo dabigatrano etexilato e os seus sais farmaceuticamente aceitáveisInfo
- Publication number
- PT2588090T PT2588090T PT117324053T PT11732405T PT2588090T PT 2588090 T PT2588090 T PT 2588090T PT 117324053 T PT117324053 T PT 117324053T PT 11732405 T PT11732405 T PT 11732405T PT 2588090 T PT2588090 T PT 2588090T
- Authority
- PT
- Portugal
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- dosage forms
- oral dosage
- dabigatran etexilate
- Prior art date
Links
- 229960000288 dabigatran etexilate Drugs 0.000 title 1
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI201000196 | 2010-07-01 | ||
| SI201000209 | 2010-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2588090T true PT2588090T (pt) | 2017-06-26 |
Family
ID=44628481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT117324053T PT2588090T (pt) | 2010-07-01 | 2011-07-01 | Formas de dosagem oral farmacêuticas compreendendo dabigatrano etexilato e os seus sais farmaceuticamente aceitáveis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20130177652A1 (pt) |
| EP (1) | EP2588090B2 (pt) |
| EA (1) | EA022969B1 (pt) |
| ES (1) | ES2631980T3 (pt) |
| PL (1) | PL2588090T3 (pt) |
| PT (1) | PT2588090T (pt) |
| SI (1) | SI2588090T1 (pt) |
| WO (1) | WO2012001156A2 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110123774A (zh) | 2012-02-21 | 2019-08-16 | 埃斯蒂维制药有限公司 | 达比加群酯的口服药物组合物 |
| WO2014060545A1 (en) * | 2012-10-19 | 2014-04-24 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions of dabigatran free base |
| EP2740471B1 (en) | 2012-12-07 | 2015-05-27 | Hexal AG | Oral pharmaceutical composition comprising dabigatran etexilate |
| CN103127109B (zh) * | 2013-02-05 | 2014-08-13 | 南京华威医药科技开发有限公司 | 含达比加群酯或其盐和水合物的药用组合 |
| EP2835370A1 (en) | 2013-08-08 | 2015-02-11 | Medichem, S.A. | New crystals of dabigatran etexilate mesylate |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| CN104994856A (zh) * | 2014-01-30 | 2015-10-21 | 杭州领业医药科技有限公司 | 达比加群酯及其盐的投药制剂及其制备方法 |
| US20150366813A1 (en) * | 2014-06-20 | 2015-12-24 | Banner Life Sciences Llc | Liquid-filled immediate release soft gelatin capsules |
| WO2016016853A1 (en) * | 2014-07-31 | 2016-02-04 | Sun Pharmaceutical Industries Limited | Method of controlling carbamoyl impurity in pharmaceutical compositions of dabigatran |
| CN105640909B (zh) | 2014-11-14 | 2019-09-20 | 正大天晴药业集团股份有限公司 | 一种含有达比加群酯的药用组合物 |
| TR201706848A2 (tr) | 2017-05-10 | 2018-11-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
| WO2019004980A2 (en) | 2017-05-10 | 2019-01-03 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE |
| TR201722186A2 (tr) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin farmasöti̇k kompozi̇syonlari |
| TR201722323A2 (tr) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari |
| TR201722630A2 (pt) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | |
| WO2020032885A2 (en) * | 2018-05-04 | 2020-02-13 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Capsule-in-capsule compositions of dabigatran etexilate |
| EP3771465A1 (en) | 2019-08-01 | 2021-02-03 | Zaklady Farmaceutyczne Polpharma SA | Pharmaceutical composition comprising dabigatran etexilate |
| EP4061369A4 (en) | 2019-11-19 | 2024-04-10 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | PHARMACEUTICAL FORM WITH ACIDIC SUBSTANCE |
| CN114191394A (zh) * | 2020-09-02 | 2022-03-18 | 北京四环制药有限公司 | 一种达比加群酯药物组合物及其制备方法和其应用 |
| WO2023139243A1 (en) | 2022-01-21 | 2023-07-27 | Adamed Pharma S.A | A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran |
| WO2024217830A1 (en) | 2023-03-30 | 2024-10-24 | Adamed Pharma S.A | A process for preparation of hard capsules filled with dabigatran pellets |
| CN116687877B (zh) * | 2023-08-07 | 2023-11-10 | 山东国邦药业有限公司 | 一种酒石酸泰万菌素干混悬剂及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| NZ535663A (en) | 2002-03-07 | 2006-06-30 | Boehringer Ingelheim Pharma | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof |
| DE10337697A1 (de) | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
| DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| DE10341043A1 (de) | 2003-09-03 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze |
| WO2009097156A1 (en) | 2008-02-01 | 2009-08-06 | Barr Laboratories, Inc. | Pharmaceutical capsules comprising extended release dipyridamole pellets |
| RU2010143901A (ru) | 2008-03-28 | 2012-05-10 | Бёрингер Ингельхайм Интернациональ Гмбх (De) | Способ получения композиций дабигатрана для перорального введения |
| US20120276206A1 (en) | 2008-03-28 | 2012-11-01 | Boehringer Ingelheim International Gmbh | Method for manufacturing acid pellets |
| US8277804B2 (en) * | 2008-05-21 | 2012-10-02 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| RU2529798C2 (ru) | 2008-07-14 | 2014-09-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ получения лекарственных соединений, содержащих дабигатран |
-
2011
- 2011-07-01 US US13/807,882 patent/US20130177652A1/en not_active Abandoned
- 2011-07-01 EP EP11732405.3A patent/EP2588090B2/en active Active
- 2011-07-01 EA EA201291421A patent/EA022969B1/ru unknown
- 2011-07-01 PL PL11732405T patent/PL2588090T3/pl unknown
- 2011-07-01 ES ES11732405.3T patent/ES2631980T3/es active Active
- 2011-07-01 WO PCT/EP2011/061140 patent/WO2012001156A2/en not_active Ceased
- 2011-07-01 PT PT117324053T patent/PT2588090T/pt unknown
- 2011-07-01 SI SI201131189A patent/SI2588090T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012001156A2 (en) | 2012-01-05 |
| EP2588090A2 (en) | 2013-05-08 |
| WO2012001156A3 (en) | 2012-08-30 |
| SI2588090T1 (sl) | 2017-06-30 |
| EA201291421A1 (ru) | 2013-05-30 |
| EP2588090B1 (en) | 2017-04-19 |
| ES2631980T3 (es) | 2017-09-07 |
| PL2588090T3 (pl) | 2017-12-29 |
| EA022969B1 (ru) | 2016-03-31 |
| US20130177652A1 (en) | 2013-07-11 |
| EP2588090B2 (en) | 2023-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2588090T1 (sl) | Trdne peroralne farmacevtske oblike, ki obsegajo dabigatran eteksilat in njegove farmacevtsko sprejemljive soli | |
| IL230819A0 (en) | Refractory oral pharmaceutical dosage form containing an opioid agonist and an opioid antagonist | |
| IL272501A (en) | Oral administration forms of bendamustine and their medical use | |
| ZA201405855B (en) | Oral pharmaceutical compositions of dabigatran etexilate | |
| LT2493474T (lt) | Būdai ir kompozicijos prolonguotam vaistų įvedimui | |
| IL219120A (en) | Cyclohaphtha pyridinyl derivatives and their use in drug preparation | |
| IL222919A (en) | Alcohol-resistant oral form | |
| IL231485A (en) | Oral dosage forms of medicinal preparations are resistant to abuse | |
| ZA201509239B (en) | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration | |
| IL221742A (en) | Oral Pharmaceuticals Containing Debigtran Etxylate | |
| SI2400954T1 (sl) | Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli | |
| IL223543A (en) | Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition | |
| PL3095441T3 (pl) | Szybko rozpuszczająca się w jamie ustnej postać dawkowania szczepionki z wykorzystaniem skrobi | |
| IL214420A0 (en) | Pharmaceutical compositions comprising tamsulosin and solifenacin for oral administration | |
| ZA201405756B (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| IL232970A0 (en) | Oral spray compounds | |
| EP2456439A4 (en) | STABLE PHARMACEUTICAL OMEPRAZOLE FORMULATION FOR ORAL ADMINISTRATION | |
| PL3067353T3 (pl) | Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania | |
| SI2654729T1 (sl) | Homogene farmacevtske oralne dozirne oblike, ki obsegajo lerkanidipin in enalapril ali njune farmacevtsko sprejemljive soli skupaj z organsko kislino | |
| SI2585051T1 (sl) | Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli | |
| PL2714042T3 (pl) | Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego | |
| EP2386301A4 (en) | PHARMACEUTICAL COMPOSITION OF LEVOAMLOPIDINE OR PHARMACEUTICAL ACCEPTABLE SALTS AND BETA BLOCKERS, AND USE THEREOF | |
| HU0900482D0 (en) | Pharmaceutical formulation for oral administration | |
| EP2529755A4 (en) | PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION |